In Financial Times Article, Michael Beauvais Discusses Life Sciences Regulatory Scrutiny Raising Transactional Risk

In The News
January 17, 2023

In a Financial Times article analyzing the decline in dealmaking following the J.P. Morgan Healthcare Conference, life sciences partner Michael Beauvais explained that regulatory scrutiny has raised transactional risk in the life sciences sector.

Michael notes the Federal Trade Commission is being aggressive in examining some transactions and looking at private equity buyers that are serial acquirers. “This is causing concern for companies because it can be disastrous if a publicly announced deal does not progress, particularly for a target,” said Michael.